**Form – 2**

**(Version 2.0 – w.e.f. 01.05.2022)**

**lnkpkj lfefr**

**Institute Ethics Committee**

अखिल भारतीय आयुर्विज्ञान संस्थान, रायपुर (छत्तीसगढ़)

**All India Institute of Medical Sciences, Raipur (Chhattisgarh)**

Website :[www.aiimsraipur.edu.in](http://www.aiimsraipur.edu.in) , Email :[iec@aiimsraipur.edu.in](mailto:iec@aiimsraipur.edu.in)

Ethics Committee Registration No.: ECR/714/Inst/CT/2015/RR-21

DHR Ethics Committee Registration No. : EC/NEW/INST/2022/CG/0075



Logo of the Institute

General Instructions: a) Tick one or more options as applicable. Mark NA if not applicable

b) Attach additional sheets if required

# SECTION A - BASIC INFORMATION

1. ADMINISTRATIVE DETAILS

(a) Name of Organization: ………………………………………………………………………………………………..........................……………………..........

(b) Name of Ethics Committee: …………………………………………………………………………………………..................................………..…………

(c) Name of Principal Investigator: ………………………………………………………………………………….........................………………..……………

(d) Department/Division: (e) Date of submission:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

(f) Type of review requested1:

Exemption from review  Expedited review  Full committee review 

(g) Title of the study: ………………….........................……………………………………………………………………………………………………………………

……………………………………………………………………………………………………………………………………................................………………………..

…………………………………………………………………………………………………………………………………................................…………………………..

Acronym/ Short title, (If any): ……………………………………………………………………………............................………………….......………

(h) Protocol number (If any): ……………………………………………………… Version number: ……………………………….......…...………

1. Details of Investigators:

|  |  |  |  |
| --- | --- | --- | --- |
| Name | Designation and Qualification | Department and Institution | Address for communication  *(Include telephone/mobile, fax numbers and email id)* |
| Principal Investigator/MBBS/PG/Superspeciality student | | | |
|  |  |  |  |
| Co-investigator/student/fellow/Guide/ Co-guide | | | |
|  |  |  |  |

1. Number of studies where applicant is a:
   1. Principal Investigator at time of submission ii) Co-Investigator at time of submission:

………………………………………………………...............………. ……………………...........………………….………………...............………..... (k) Duration of the study: …………………………………………………………………………………………………………..…………...........................………

***1****Refer to National Ethical Guidelines for Biomedical and Health Research Involving Human Participants 2017 on Page 36 Table 4.2. for types of review*

1. FUNDING DETAILS AND BUDGET

(a) Total estimated budget for site: …………………………………………………………………………………………………….......................……………

At site…………………………….................... In India…………………………...…………… Globally ………………........…...................................

(b) Self-funding  Institutional funding  Funding agency *(Specify)* 

..........………....………….....................................................…………………............................................................................................................

SECTION B - RESEARCH RELATED INFORMATION

1. OVERVIEW OF RESEARCH

(a) Lay summary3 (within 300 words): ……………………..................................…………………………………………….....………………………...

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

(b) Type of study:

|  |  |  |
| --- | --- | --- |
| Basic Sciences  Clinical Trial |  Cross Sectional |  |
| Retrospective  Epidemiological/ |  Case Control |  |
| Prospective  Public Health | Cohort |  |
| Qualitative  Socio-behavioural |  Systematic Review |  |
| Quantitative  Biological samples/ Data |  |  |
| Mixed Method  Any others *(Specify)* |  |  |

..........................................................................................................................................................………............…………………................

1. METHODOLOGY
   1. Sample size/ number of participants *(as applicable)*

At site…………………………….................... In India…………………………...…………… Globally ………………........…...................................

Control group………………………………………………………………… Study group ……………………………….…......….........................………

Justification for the sample size chosen (100 words); In case of qualitative study, mention the criteria used for saturation ...................………………………………………………………………………………………………………………………………….........................

...............…………………………………………………………………………………………...………………………………………………….....................….......…

………..................................…………………………………………………………….....……………….…………………………………………………………………

………..................................…………………………………………………………….....………………….………………………………………………………………

*3Summarize in the simplest possible way such that a person with no prior knowledge of the subject can easily understand it.*

* 1. Is there an external laboratory/outsourcing involved for investigations?4 Yes  No  NA 
  2. How was the scientific quality of the study assessed?

Independent external review  Review by sponsor/Funder  Review within PI’s institution 

Review within multi-centre  No review 

research group Date of review:

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

Comments of scientific committee, if any (100 words)

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

..................................……………………………………………………………………………………………………………………………………………………………

SECTION C: PARTICIPANT RELATED INFORMATION

1. RECRUITMENT AND RESEARCH PARTICIPANTS
   1. Type of participants in the study:

Healthy volunteers  Patients  Vulnerable persons/ Special groups 

Others  *(Specify)* .................................................................................................…........…………...........................

Who will do the recruitment? ……………………………………………………………………………………………………………………......................

Participant recruitment methods used:

Posters/ 

leaflets/Letters

TV/Radio ads/  Social media/ Institution website

Patients / Family/ Friends 

visiting hospitals

Telephone 

Others  *(Specify)* ……………………………………...................................................................................................……

* 1. i. Will there be vulnerable persons / special groups involved? Yes  No  NA 

ii. If yes, type of vulnerable persons / special groups

Children under 18 yrs  Pregnant or lactating women  Differently abled (Mental/Physical)  Employees/Students/Nurses/Staff  Elderly  Institutionalized  Economically and socially disadvantaged  Refugees/Migrants/Homeless  Terminally ill (stigmatized or rare diseases) 

Any other *(Specify)*:  ……………………......................................................................................

iii. Provide justification for inclusion/exclusion …………………………………………………………………………..................………………..

…………………………………………………………………………………………………………………………………………………………….…....…………………

…………………………………………………………………………………………………………………………………………………………….…....………………… iv. Are there any additional safeguards to protect research participants?..........................................................................

…………………………………………………………………………………………………………………………………………………………….…....…………………

…………………………………………………………………………………………………………………………………………………………….…....…………………

*4If participant samples are sent outside for investigations, provide details of the same and attach relevant documentation such as an MTA / MoU*

* 1. Is there any reimbursement to the participants? Yes  No 

If yes, Monetary  Non-monetary  *Provide details*

……………………………………………………………………………………………….....………………………………….……………………….………………….........

* 1. Are there any incentives to the participants? Yes  No 

If yes, Monetary  Non-monetary  *Provide details*

…………………………………………………………………………………………………………………………....................................................................….

* 1. Are there any participant recruitment fees/ incentives for the study provided to the PI / Institution?

If yes, Monetary  Non-monetary  *Provide details* Yes  No 

……………………………………………………………………….….………………………………………………………………………………………………………………

…………………………………………………………………………...……………………………………………………….……………………….……………….…….......

1. BENEFITS AND RISKS
   1. i. Are there any anticipated physical/social/psychological discomforts/ risk to participants? Yes  No 

If yes, categorize the level of risk5:

Less than Minimal risk  Minimal risk 

Minor increase over minimal risk or low risk  More than minimal risk or high risk 

ii. Describe the risk management strategy: …………………………………………………………………………………....................................

..…………………………………………………..…………….….……………………………………………………………………………………………….....………....

..…………………………………………………..…………….….……………………………………………………………………………………………….....………....

* 1. What are the potential benefits from the study? For the participant

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Yes | No | If yes, | Direct | Indirect |
|      |      |  |      |      |

For the society/community For improvement in science

Please describe how the benefits justify the risks …………………………………………………………………………………………..……………

………………………………………………………………………….….…………………………………………………………………………………………….………………

………………………………………………………………………….….……………………………………………………………………………………………….……………

………………………………………………………………………….….……………………………………………………………………………………………….……………

* 1. Are adverse events expected in the study6 ? Yes  No  NA  Are reporting procedures and management strategies described in the study? Yes  No  If Yes, Specify …………………………………………………………………................................……………………………………………………………………

…………………......……………………………………………………….….……………………………………………………………………………………………………….

..................................................................................................................................................................................................................

1. INFORMED CONSENT
   1. Are you seeking waiver of consent? If yes, please specify reasons and skip to item no. 8 Yes  No 

.....................………………………………………………………………………………………………………………………….…………….....…………..………………

.....................………………………………………………………………………………………………………………………….…………....………………………………

*5For categories of risk refer to National Ethical Guidelines for Biomedical & Health Research Involving Human Participants 2017, Page 6 Table 2.1*

*6The term adverse events in this regard encompass both serious and non-serious adverse events.*

* 1. Version number and date of Participant Information Sheet (PIS):…………………………………......................………………………

Version number and date of Informed Consent Form (ICF):……………………………………………….......................………………

* 1. Type of consent planned for :

Signed consent  Verbal/Oral consent  Witnessed consent 

Audio-Video (AV) 

consent

Consent from LAR 

(If so, specify from whom)

.....................................................

Other 

For children<7 yrs 

parental/LAR consent

Verbal assent from  minor (7-12 yrs) along with parental consent

Written assent from  minor (13-18 yrs) along with parental consent

*(specify)* ..............................................................................................................................................................................................

* 1. Who will obtain the informed consent?

PI/Co-I  Nurse/Counselor  Research Staff  Other  (*Specify)* ………….............................……...

Any tools to be used ……………………………………………………………………………………………………………............................……………....

* 1. Participant Information Sheet (PIS) and Informed Consent Form (ICF)

English  Local language  Other  *(Specify)*………………………........................................……...

List the languages in which translations were done ………………………………....................…………………….….……………….....……

If translation has not been done, please justify …………………………………………………………….....................….….………………......

* 1. Provide details of consent requirements for previously stored samples if used in the study7

....................………………………………………………………………………………………………………………………….…………....………………………………

* 1. Elements contained in the Participant Information Sheet(PIS) and Informed Consent Form (ICF)

Simple language 

Risks and discomforts  Alternatives to participation  Right to withdraw 

Benefits 

Purpose and procedure 

Others(Specify) 

Data/ Sample sharing 

Need to recontact 

Confidentiality 

Storage of samples  Return of research results  Payment for participation 

Compensation for study related injury  Statement that consent is voluntary  Commercialization/ Benefit sharing  Statement that study involves research  Use of photographs/ Identifying data  Contact information of PI and Member  Secretary of EC

.........................………………………………………………………………………………………………………………………….…………....………………………………

1. PAYMENT/COMPENSATION
   1. Who will bear the costs related to participation and procedures8 ?

PI  Institution  Sponsor  Other agencies  *(specify)*

………………………………….......................................................................................................................................................................…

* 1. Is there a provision for free treatment of research related injuries? Yes  No  N/A 

If yes, then who will provide the treatment? …………………………………………………………………………………………..........................

* 1. Is there a provision for compensation of research related SAE? If yes, specify. Yes  No  N/A 

Sponsor  Institutional/Corpus fund  Project grant  Insurance 

* 1. Is there any provision for medical treatment or management till the relatedness is determined for injury to the participants during the study period? If yes, specify. Yes  No  N/A 

.........................………………………………………………………………………………………………………………………….…………………………………………

* 1. Is there a provision for ancillary care for unrelated illness during the study period? If yes, please specify.

Yes  No  N/A 

*7Information on re-consent requirements can be found at National Ethical Guidelines for Biomedical and Health Research Involving Human Participants 2017, Page 54 in Section 5.8.*

*8Enclose undertaking from PI confirming the same*

1. STORAGE AND CONFIDENTIALITY
   1. Identifying Information: Study Involves samples/data. *If Yes, specify* Yes  No  NA  Anonymous/Unidentified  Anonymized: Reversibly coded  Irreversibly coded  Identifiable  If identifiers must be retained, what additional precautions will be taken to ensure that access is limited /data is safeguarded? (e.g. data stored in a cabinet, password protected computer etc.) …………………………………………………….

....…………………………………………………………………………………………………………………………..……………...............................…………………

....…………………………………………………………………………………………………………………………..……………...............................…………………

....…………………………………………………………………………………………………………………………..……………...............................…………………

....…………………………………………………………………………………………………………………………..……………...............................………………… (b) Who will be maintaining the data pertaining to the study? …………..……….......................………………………………………………. (c) Where will the data be analyzed9 and by whom? ……………………….……………………..............................……………………………..

(d) For how long will the data be stored? ………………………………………...………………………........................…………………………………

(e) Do you propose to use stored samples/data in future studies? Yes  No  Maybe 

If yes, explain how you might use stored material/data in the future?...................................................................................

....…………………………………………………………………………………………………………………………..……………...............................…………………

....…………………………………………………………………………………………………………………………..……………...............................…………………

....…………………………………………………………………………………………………………………………..……………...............................…………………

SECTION D: OTHER ISSUES

1. PUBLICATION, BENEFIT SHARING AND IPR ISSUES
   1. Will the results of the study be reported and disseminated? If yes, specify. Yes  No  NA 

.…………......……………………………………………………….….………………………………………………………………………………………………………………

.…………......……………………………………………………….….………………………………………………………………………………………………………………

* 1. Will you inform participants about the results of the study? Yes  No  NA 
  2. Are there any arrangements for continued provision of the intervention for participants, if effective, once the study has finished? If yes describe in brief (Max 50 words) Yes  No  NA 

.…………......……………………………………………………….….………………………………………………………………………………………………………………

.…………......……………………………………………………….….………………………………………………………………………………………………………………

* 1. Is there any plan for post research benefit sharing with participants? If yes, *specify* Yes  No  NA 

.…………......……………………………………………………….….………………………………………………………………………………………………………………

.…………......……………………………………………………….….………………………………………………………………………………………………………………

* 1. Is there any commercial value or a plan to patent/IPR issues? If yes, please provide details Yes  No  NA 

.…………......……………………………………………………….….………………………………………………………………………………………………………………

* 1. Do you have any additional information to add in support of the application, which is not included elsewhere in the form? If yes, provide details. Yes  No 

.…………......……………………………………………………….….………………………………………………………………………………………………………………

.…………......……………………………………………………….….………………………………………………………………………………………………………………

9*For example, a data entry room, a protected computer etc.*

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

SECTION E: DECLARATION AND CHECKLIST 10

|  |  |
| --- | --- |
| 11. DECLARATION (Please tick as applicable) | |
|  | I/We certify that the information provided in this application is complete and correct. |
|  | I/We confirm that all investigators have approved the submitted version of proposal/related documents. |
|  | I/We confirm that this study will be conducted in accordance with the latest ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants and other applicable regulations and guide- lines. |
|  | I/We confirm that this study will be conducted in accordance with the Drugs and Cosmetics Act 1940 and its Rules 1945 as amended from time to time, GCP guidelines and other applicable regulations and guidelines. |
|  | I/We will comply with all policies and guidelines of the institute and affiliated/collaborating institutions where this study will be conducted. |
|  | I/We will ensure that personnel performing this study are qualified, appropriately trained and will adhere to the provisions of the EC approved protocol. |
|  | I/We declare that the expenditure in case of injury related to the study will be taken care of. |
|  | I/We confirm that an undertaking of what will be done with the leftover samples is provided, if applicable. |
|  | I/We confirm that we shall submit any protocol amendments, adverse events report, significant deviations from protocols, progress reports and a final report and also participate in any audit of the study if needed. |
|  | I/We confirm that we will maintain accurate and complete records of all aspects of the study. |
|  | I/We will protect the privacy of participants and assure confidentiality of data and biological samples. |
|  | I/We hereby declare that I/any of the investigators, researchers and/or close relative(s), have no conflict of interest (Financial/Non-Financial) with the sponsor(s) and outcome of study. |
|  | I/We have the following conflict of interest (PI/Co-I):  1. .....................................................................................................................................................................................................  2. .................................................................................................................................................................................................... |
|  | I/We declare/confirm that all necessary government approvals will be obtained as per requirements where- er applicable. |
| Name of PI /MBBS/PG/Superspeciality student ………………....................................................................................................................................……………......................  Signature: ........................……………………………….............................................................................................  Name of Co-PI/Guide: .................................................................................................................................…………………………….................  Signature: ........................……………………………….............................................................................................  Name of Co-PI/Co-Guide: ..................................................................................................................................…………………………….................  Signature: ........................……………………………….............................................................................................  Name of HOD: ..................................................................................................................................…………………………….................  Signature: ........................………………………………............................................................................................. | |

*10These formats are adaptable and can be modified by the Ethics Committee members depending on their needs and requirements Acknowledgement for Receipt of Application (Copy to be provided to PI)*

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |
| --- | --- | --- |
| dd | mm | yy |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 12. CHECKLIST | | | | | | | | | | | | | |
| S. No | Items | | | | | | | | Yes | No | NA | Enclosure No | EC Remarks (If applicable) |
| ADMINISTRATIVE REQUIREMENTS | | | | | | | | | | | | | |
| 1 | Cover letter | | | | | | | |  |  |  |  |  |
| 2 | Brief CV of all Investigators | | | | | | | |  |  |  |  |  |
| 3 | Good Clinical Practice (GCP) training of investigators in last 3 years | | | | | | | |  |  |  |  |  |
| 4 | Approval of scientific committee | | | | | | | |  |  |  |  |  |
| 5 | EC clearance of other centers\* | | | | | | | |  |  |  |  |  |
| 6 | Agreement between collaborating partners\* | | | | | | | |  |  |  |  |  |
| 7 | MTA between collaborating partners\* | | | | | | | |  |  |  |  |  |
| 8 | Insurance policy/certificate | | | | | | | |  |  |  |  |  |
| 9 | Evidence of external laboratory credentials in case of an externally outsourced laboratory study QA/QC certification | | | | | | | |  |  |  |  |  |
| 10 | Copy of contract or agreement signed with the sponsor or donor agency | | | | | | | |  |  |  |  |  |
| 11 | Provide all significant previous decisions (e.g. those leading to a negative decision or modified protocol) by other ECs/Regulatory authorities for proposed study (whether in same location or elsewhere) and modification(s) to protocol | | | | | | | |  |  |  |  |  |
| PROPOSAL RELATED | | | | | | | | | | | | | |
| 12 | Copy of the detailed protocol11 | | | | | | | |  |  |  |  |  |
| 13 | Investigators Brochure (If applicable for drug/ biological /device trials) | | | | | | | |  |  |  |  |  |
| 14 | Participant Information Sheet (PIS) and Participant Informed Consent Form (ICF)(English and translated) | | | | | | | |  |  |  |  |  |
| 15 | Assent form for minors (12-18 years) (English and Translated) | | | | | | | |  |  |  |  |  |
| 16 | Proforma/Questionnaire / Case Report Forms (CRF)/ Interview guides/ Guides for Focused Group Discussions (FGDs) (English and translated) | | | | | | | |  |  |  |  |  |
| 17 | Advertisement/material to recruit participants (fliers, posters etc) | | | | | | | |  |  |  |  |  |
| PERMISSION FROM GOVERNING AUTHORITIES | | | | | | | | | | | | | |
|  | **Other permissions** | **Required** | | **Not required** | | **Received** | | **Applied dd/ mm/yy** | **EC Remarks** | | | | |
| 18 | CTRI |  | |  | |  | |  |  | | | | |
| 19 | DCGI |  | |  | |  | |  |  | | | | |
| 20 | HMSC |  | |  | |  | |  |  | | | | |
| 21 | NAC-SCRT |  | |  | |  | |  |  | | | | |
| 22 | ICSCR |  | |  | |  | |  |  | | | | |
| 23 | RCGM |  | |  | |  | |  |  | | | | |
| 24 | GEAC |  | |  | |  | |  |  | | | | |
| 25 | BARC |  | |  | |  | |  |  | | | | |
| 26 | Tribal Board |  | |  | |  | |  |  | | | | |
| 27 | Others (Specify) |  | |  | |  | |  |  | | | | |
| ANY OTHER RELEVANT INFORMATION/DOCUMENTS RELATED TO THE STUDY | | | | | | | | | | | | | |
|  | **Item** | | **YES** | | **NO** | **NA** | **Enclosure no.** | | **EC remarks** | | | | |
| 28 |  | |  | |  |  |  | |  | | | | |
| 29 |  | |  | |  |  |  | |  | | | | |

*\*For multicentre research.*

*MTA-Material transfer agreement; CTRI-Clinical Trial Registry-India; DCGI-Drug Controller General of India; HMSC- Health Ministry’s Screening Committee; NAC-SCRT- National Apex Committee for Stem Cell Research and Therapy; IC-SCR-Institutional committee for Stem Cell Research; RCGM- Review Com-mittee on Genetic Manipulation; GEAC- Genetic Engineering Approval Committee; BARC- Bhabha Atomic Research Centre*

11*Refer to National Ethical Guidelines for Biomedical and Health Research Involving Human Participants 2017, section 4 Page no. 35 Box 4.4(b)*